Viewing nowPregabalin Orally Disintegrating Tablets 50 mg (Pregabalin)
Pregabalin 50mg
Orally disintegrating Tablet · Prescription medication
Huons Co., Ltd.

MFDS item code 202600537 · Approved 2026.02.24
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures
This medication is used to alleviate peripheral and central neuropathic pain in adults. Additionally, it serves as an adjunctive treatment for partial seizures in patients with epilepsy, applicable in both cases with or without systemic symptoms. Furthermore, it is effective in relieving pain caused by fibromyalgia. It is used for improving various neuropathic pain and symptoms.
This medicine should be administered orally as pregabalin in 2 divided doses per day, regardless of food. Place it on the tongue and, once it has disintegrated, swallow it without water. This medicine is primarily excreted by the kidneys; therefore, the dosage should be adjusted in patients with impaired renal function. (See ‘5. Patients with Renal Impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose according to renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Initial dose 25, maximum dose 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under the method of administration. b: The supplemental dose refers to a dose administered as a single additional dose. 6. Patients with Hepatic Impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behavior, so careful monitoring for mood changes or abnormal behavior is necessary during treatment. Patients with hypersensitivity to this medication should not take it. Diabetic patients may experience weight gain from this medication, necessitating dosage adjustment of blood glucose control medications. In the event of severe allergic reactions such as angioedema, discontinue use immediately and consult a healthcare professional. Elderly patients are cautioned against the risk of falls or injuries due to dizziness or drowsiness that may occur with this medication. Visual disturbances or changes in eyesight may occur, and symptoms may improve upon discontinuation of the medication. Discontinuation of this medication may lead to withdrawal symptoms such as insomnia, headaches, and anxiety, so it should be gradually reduced according to a doctor's instructions. Patients with a history of substance abuse should take this medication cautiously due to the potential for misuse or abuse. Patients with reduced kidney function may require dosage adjustments, and the improvement of kidney function should be monitored in consultation with healthcare professionals. Patients with heart disease should be cautious as this medication may increase the risk of congestive heart failure. Co-administration with opioid analgesics may enhance the central nervous system depressant effects, leading to respiratory depression risk. Patients with weakened respiratory function or the elderly may face a higher risk of severe respiratory depression, requiring possible dosage adjustments. In the early stages of pregnancy, there is a risk of fetal malformations, so pregnant women should not take this medication, and women of childbearing age should use effective contraception. This medication can cause dizziness and drowsiness; therefore, driving or operating hazardous machinery should be avoided until symptoms are confirmed. Severe skin reactions may rarely occur; if a rash or blistering appears, discontinue use immediately and consult a physician. This medication has low pharmacokinetic interactions with other drugs, but when combined with central nervous system depressants, side effects may increase, so caution is advised. During breastfeeding, as this medication can pass into breast milk and affect infants, it may be prudent to either discontinue nursing or stop taking the medication. Elderly patients may experience delayed excretion of this medication due to reduced kidney function, necessitating dosage adjustments. In cases of overdose, symptoms such as drowsiness, confusion, depression, and seizures may occur, requiring immediate treatment in a medical facility. This medication should be stored out of reach of children, and transferring it to another container could lead to accidents.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it should be stored in a sealed container. It is best to maintain the storage temperature between 1°C and 30°C to preserve the effectiveness and safety of the medication.
Yellow round orally disintegrating tablet
30 tablets/PTP [10 tablets/PTP x 3], 100 tablets/PTP [10 tablets/PTP x 10]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 50mg
Orally disintegrating Tablet · Prescription medication
Huons Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.